Vigil Neuroscience, Inc. (VIGL) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Watertown, MA, United States. The current CEO is Ivana Magovcevic-Liebisch.
VIGL has IPO date of 2022-01-07, 69 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $375.71M.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
